p53 or TCF/LEF TFD DNA-based therapy could be combined with existing CRC treatments such as chemotherapy or immunotherapy to obtain synergistic effects, and the combination of p53 restoration and modulation of Wnt signaling might also enhance therapeutic efficacy. This evidence concerns the gene TP53 and colorectal carcinoma.